ArticleJAMA network open2025
Differences in the Cancer Burden and Current Funding of NCI-Designated Cancer Centers.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating Patient Experience With Genomic Medicine: A Content Analysis of National Cancer Institute-Designated Cancer Centers' Websites.JMIR cancer · 2025Article
- Errors in Figure 1 and Figure 4B.JAMA network open · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: National Cancer Institute (NCI)-designated clinical and comprehensive cancer centers are required to define a geographic catchment area (CA) in which they focus research, outreach, and engagement efforts for the purposes of reducing cancer burden, particularly among certain vulnerable populations. A comprehensive analysis of the cancer burden of these catchment areas and their association with cancer center funding through the Cancer Center Support Grant (CCSG) has not been performed. Objective: To examine CA cancer burden indicators and cancer center CCSG funding during the 2023 federal fiscal year (FY23). Design, Setting, and Participants: This population-based cross-sectional study assessed cancer center cancer rates, sociodemographic variables, and reported CCSG funding. Participants included NCI-Designated Clinical and Comprehensive Cancer Centers as of FY23. Data were analyzed from August to December 2024. Exposures: Race and ethnicity, socioeconomic status, disability status, urbanicity. Main Outcomes and Measures: Main outcomes included CA cancer rates with 95% CI and various population percentage estimates, as well as cancer center CCSG direct costs for FY23. Adjusted CCSG funding by CA population size was also assessed. The association between cancer burden indicators and population-adjusted CCSG funding was estimated using Spearman rank correlation. Results: This study included 64 NCI-Designated Cancer Centers (11 clinical [17.2%], 53 comprehensive [82.8%]) with CAs covering 297 040 253 people. Individual CA populations ranged from 1.4 million to 29.9 million people, with substantial variation in sociodemographic compositions. CA cancer incidence ranged from 369.2 (95% CI, 367.5 to 370.8) to 518.7 (95% CI, 514.2 to 523.2) cases per 100 000 persons. Cancer mortality ranged from 115.2 (95% CI, 114.3 to 116.1) to 181.1 (95% CI, 179.5 to 182.7) deaths per 100 000 persons. Population-adjusted CCSG funding showed no association with cancer rates, but was positively associated with rural populations (r = 0.356; 95% CI, 0.119 to 0.555) and persons living with a disability (r = 0.378; 95% CI, 0.143 to 0.572) and negatively associated with populations belonging to a racial or ethnic minority group (r = -0.354; 95% CI, -0.553 to -0.116). Conclusions and Relevance: In this cross-sectional study of NCI-Designated Cancer Centers, there were substantial disparities in cancer burden across catchment areas. CCSG funding did not align well with this distribution, raising questions about whether funding allocations effectively support cancer centers serving high-need CAs. In addition to existing criteria, consideration of CA cancer burden and vulnerable populations in determining CCSG funding amounts could enhance efforts to reduce cancer burden and disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.